Nonalcoholic fatty liver disease and the epidemic of obesity

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Rochelle Collantes, MD, MPH
Research Associate, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Janus P. Ong, MD
Staff Hepatologist, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Zobair M. Younossi, MD, MPH
Director, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA

Address: Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.